Manuscript for Review Process
One Year Follow up of 50 Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) after Pharmacological Treatment
Abstract:
Non-Alcoholic Fatty Liver Disease (NAFLD), is one of the most prevalent liver diseases
worldwide which is raised up increasingly in incidence and prevalence (1). It is defined by
liver accumulation of triglycerides and free fatty acids (2). Metabolic risk factors associated
with NAFLD are obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia (3). NAFLD
patients may develop progressive fibrosis which yields eventually to progressive steatosis with
associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma (HCC)
(4).
Keywords:
Non-Alcoholic Fatty Liver Disease, Metformin, Dyslipidemia.
